salvage therapy-H. Lee Moffitt Cancer Center and Research Institute-prostate cancer

This refers to a specific chemohormonal treatment regimen investigated in a Phase 2 clinical trial (NCT01531205) by the H. Lee Moffitt Cancer Center and Research Institute for patients with locally recurrent prostate cancer following initial radiotherapy. The regimen consists of neoadjuvant cabazitaxel, a semi-synthetic taxane chemotherapy agent that inhibits microtubule depolymerization and cell division, combined with androgen deprivation therapy (ADT) using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide or goserelin acetate. Daily oral prednisone is also administered throughout the cabazitaxel treatment cycles. This neoadjuvant therapy is intended to be followed by salvage surgery (prostatectomy) to evaluate pathological complete response rates and improve surgical outcomes in high-risk patients experiencing PSA failure with biopsy-proven local recurrence.

Brand names

Jevtana

Other names

cabazitaxel + androgen deprivation therapy + prednisoneneoadjuvant chemohormonal therapycabazitaxel + leuprolide + prednisonecabazitaxel + goserelin + prednisone